Adaptilens is a Boston, MA-based pre-clinical biotech focused on advancing the standard of care for cataract surgery. Its core product, the Adaptilens A-IOL, is a soft, flexible, biomimetic accommodating intraocular lens that responds to the eye's natural signal to focus and aims to eliminate the need for eyeglasses or contact lenses. The company intends to use the new funding to drive development of the A-IOL through first-in-human trials. Adaptilens is led by founder and CEO Liane Clamen. The company raised $17.5M in a Series A round led by Perceptive Xontogeny Venture Funds, with participation from Pillar VC, 380 Cap, and Accanto Partners. As a pre-clinical company, its near-term milestones are clinical development steps rather than commercial deployment. Adaptilens is a Boston, MA-based company developing an accommodating intraocular lens (AdaptilensTM) that mimics the natural human lens. Led by Founder and CEO Dr. Liane Clamen, the device aims to give patients excellent near, intermediate, and distance vision without eyeglasses or contact lenses. The lens will initially be used for patients with cataracts. Adaptilens could also be used to correct a variety of refractive errors, including presbyopia. The company raised $1.6M in seed funding to support development of the accommodating intraocular lens. The round was led by Pillar VC with participation from Accanto Partners.

Total raised

$19M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2024